Skip to main content
Ind-Swift Laboratories Ltd. logo

Ind-Swift Laboratories Ltd. — Investor Relations & Filings

Ticker · INDSWFTLAB ISIN · INE915B01019 LEI · 335800ZT8UFD9Y8ZMP56 BSE.NS Manufacturing
Open in API
Filings indexed 816 across all filing types
Latest filing 2025-02-13 Regulatory Filings
Country IN India
Listing BSE.NS INDSWFTLAB

About Ind-Swift Laboratories Ltd.

https://www.indswiftlabs.com

Ind-Swift Laboratories Ltd. is a global manufacturer specializing in Active Pharmaceutical Ingredients (APIs) and Advanced Intermediates. The company focuses on research and development, process chemistry, and large-scale production across diverse therapeutic segments, including macrolide antibiotics, cardiovascular agents, antihistamines, antidiabetics, and antipsychotics. Operating multiple manufacturing facilities that adhere to international regulatory standards such as USFDA, EDQM, and PMDA, the organization provides high-quality chemical entities to the global market. Its core competencies lie in complex chemical synthesis and the development of cost-effective manufacturing processes for generic and specialty drug substances. The company maintains a strong emphasis on quality assurance and regulatory compliance to support its extensive portfolio of products distributed worldwide.

Recent filings

Filing Released Lang Actions
Updates
Regulatory Filings Classification · 95% confidence The document is an intimation under Regulation 8 & 9 of the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015. It includes the adoption of a new Code of Fair Disclosure, Internal Procedures and Conduct for Regulating, Monitoring and Reporting of Trading by Designated Persons and Immediate Relatives, and Legitimate Purpose Policy. The document is addressed to stock exchanges and regulatory bodies, and it contains detailed policy text spanning multiple pages. It is not a financial report, earnings release, or management discussion, but rather a regulatory compliance disclosure related to insider trading regulations. It is not a report publication announcement since the full code is included, not just a notice of availability. This type of document fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other specific categories.
2025-02-13 English
Financial Result Updates
Regulatory Filings
2025-02-13 English
Outcome of Board Meeting
Regulatory Filings
2025-02-13 English
Cessation
Board/Management Information Classification · 95% confidence The document is an intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, regarding the completion of tenure of an Independent Director. It is a formal announcement notifying stock exchanges about a change in the board of directors. The document does not contain financial data, audit information, or detailed reports but rather focuses on management/board changes. Therefore, it fits the category of Board/Management Information (MANG). The document length is short and it is not a report publication announcement or regulatory filing. Hence, the classification is MANG with high confidence.
2025-02-13 English
Board Meeting — Board Meeting Intimation
Regulatory Filings
2025-02-12 English
Board Meeting — Financial Results
Regulatory Filings Classification · 95% confidence The document is a notice of adjournment of a Board Meeting originally scheduled to consider and approve the unaudited financial results for the quarter and nine months ended December 31, 2024. It states that the meeting could not be conducted due to lack of quorum and has been adjourned to a later date. The document also mentions the extension of the trading window closure period until 48 hours after the declaration of the financial results. The document does not contain the financial results themselves, nor detailed financial data or analysis. It is a regulatory announcement related to the scheduling of a board meeting and the timing of financial results release. The document length is short (2124 characters), and it serves as an intimation or notice rather than the actual financial report. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for such announcements that do not contain the actual report or detailed financial data.
2025-02-12 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.